GEA
PRME icon

Glen Eagle Advisors’s Prime Medicine PRME Stock Holding History

Glen Eagle Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4K Sell
5,000
-5,000
-50% -$16.6K ﹤0.01% 606
2026
Q1 		$34.8K Hold
10,000
– – ﹤0.01% 495
2025
Q4 		$34.7K Buy
+10,000
New +$44.5K ﹤0.01% 506

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Glen Eagle Advisors's PRME Position: Q2 2026 in Review

Glen Eagle Advisors reduced its Prime Medicine (PRME) stake by 50% in Q2 2026, selling an estimated $16.6K and leaving 5,000 shares worth $18.4K. The position accounts for ﹤0.01% of the portfolio, ranked #606.

Glen Eagle Advisors first reported a position in PRME in Q4 2025 and has held it in 3 quarters since. The position peaked at $34.8K in Q1 2026. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Glen Eagle Advisors held 5,000 shares of Prime Medicine worth $18.4K as of Q2 2026.
  • Glen Eagle Advisors sold 5,000 Prime Medicine shares in Q2 2026, an estimated $16.6K.
  • Prime Medicine made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q2 2026, its #606 holding.
  • Glen Eagle Advisors first reported a position in Prime Medicine in Q4 2025 and has held it in 3 quarters since.
  • Glen Eagle Advisors's Prime Medicine position peaked at $34.8K in Q1 2026.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Glen Eagle Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.